REG - Kanabo Group PLC - Treat It Launch: Online Medicinal Cannabis Clinic

KanaboAnnouncement

13/03/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230313:nRSM6440Sa&default-theme=true

RNS Number : 6440S  Kanabo Group PLC  13 March 2023

13 March 2023

 

Kanabo Group plc

("Kanabo", the "Group" or the "Company")

 

Launch of 'Treat It' an Online Medicinal Cannabis Clinic for Pain Management

 

'Treat It' clinic enables patients to access healthcare professionals via
Kanabo's secure, digital healthcare platform

Chronic pain sufferers to be given access to medicinal cannabis, directly
addressing growing demand across the UK for pain management

 

Kanabo Group plc (LSE: KNB), a patient-focused Healthtech company, has
launched Treat It (https://treat-it.clinic) , a new online medicinal cannabis
clinic for pain management. The new clinic aims to address the issue of
limited access to pain management treatments for the approximately 8 million
chronic pain sufferers in the UK. These individuals face difficulties
accessing medical treatments due to long waiting times, bureaucracy, and
affordability. According to recent data, 24% of chronic pain sufferers in the
UK are currently being prescribed opioids, making up approximately 3 million
of the potential patients who can benefit from switching to medicinal
cannabis.

 

Treat It (https://treat-it.clinic/) enables patients to access healthcare
professionals via Kanabo's secure, digital healthcare platform. It will be
focused on secondary care, including the prescription of medicinal cannabis.
Studies have shown that medicinal cannabis can relieve pain for a range of
common chronic pain conditions. Kanabo's existing online clinic, The GP
Service, offers patients access to experienced healthcare professionals who
can offer a broad range of treatment recommendations for primary care.

 

The growing demand for pain management treatments using medicinal cannabis is
reflected in the increase in medical cannabis prescriptions issued in the UK,
with over 89,000 issued between November 2018 and July 2022, indicating an
average growth rate of approximately 72% per year, with more than 100% growth
in 2022.

 

Avihu Tamir, CEO of Kanabo Group said:

"Our innovative healthcare platform, Treat It (https://treat-it.clinic/) ,
seeks to directly address the limited access to pain management treatments for
patients across the UK. Leveraging our proprietary technology from The GP
Service, which we have recently integrated, we have created an online
ecosystem for chronic pain sufferers, providing access to doctors and
medicinal cannabis prescriptions. Our goal is to offer patients direct access
to high-quality medical treatments; empowering patients to take control of
their own personalised care."

 

Treat It (https://treat-it.clinic) forms part of the Company's growing
technology stack, and combines proprietary digital tools and a treatment
portfolio, including patient access, online consultations, prescriptions, and
medication dispensing, into an integrated end-to-end solution. This unified
approach offers patients efficient and effective access to qualified medical
practitioners. Kanabo's treatment portfolio focuses on pain management using
medications and treatments, including medicinal cannabis, which is currently
unavailable through traditional channels. However, demand for these products
is growing as patients seek alternative pain management options.

Treat It (https://treat-it.clinic) is regulated by The Care Quality Commission
and certified with ISO 27001 for information security, will allow doctors
registered with the General Medical Council to prescribe medicinal cannabis to
patients while following the guidelines set out by the National Institute for
Health and Care Excellence.

 

 

Enquiries:

 

 Kanabo Group plc                                                  via Vigo Consulting

 Avihu Tamir, Chief Executive Officer                              +44 (0)20 7390 0230

 Assaf Vardimon, Chief Financial Officer

 Peterhouse Capital Ltd (Financial Adviser)                        +44 (0)20 7469 0930

 Eran Zucker / Lucy Williams / Charles Goodfellow

 Vigo Consulting (Financial Public Relations/Investor Relations)    +44 (0)20 7390 0230

 Jeremy Garcia / Fiona Hetherington / Verity Snow

 kanabo@vigoconsulting.com

 

 

 

About Kanabo Group Plc

Kanabo Group Plc (LSE:KNB) is a Healthtech company committed to
revolutionising patient care through its innovative technology platform and
disruptive product offerings. Since its inception in 2017, Kanabo has been
focused on researching, developing, and commercialising regulated medicinal
cannabis-derived formulations and therapeutic inhalation devices.

 

Kanabo's NHS-approved online telehealth platform, The GP Service, provides
patients with video consultations, online prescriptions, and primary care
services. The company is a leader in its field, focusing on improving patient
outcomes and providing more accessible healthcare experiences.

 

In March 2023, Kanabo successfully launched its Pain Clinic, Treat It, under
the expert guidance of its technological and product expertise. Treat It
initially focuses on chronic pain management using plant-based medicine and
treatments that are currently unavailable through traditional channels.

 

At Kanabo Group Plc, we are dedicated to providing patients with the highest
quality medical treatments and more accessible healthcare experiences.

 

Visit www.kanabogroup.com (http://www.kanabogroup.com)  for more info.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  PRLDBLFFXXLFBBL